IFAN yields 2000000.00% · ABBV yields 3.06%● Live data
📍 IFAN pulled ahead of the other in Year 1
Combined, IFAN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IFAN + ABBV for your $10,000?
IFAN Financial, Inc., together with its subsidiaries, designs, develops, and distributes software to enable mobile payments. Its products include the ability to use a debit card and corresponding PIN number while purchasing online on a mobile phone, tablet, or computer, as well as peer-to-peer cash transfers. It has a portfolio of solutions, including mobile optimized 'white label' solutions with the ability to facilitate on demand payments, autopay, proximity payments and marketing, and a proprietary linked debit cards. The company's 'white label' enterprise solutions offer mobile banking products and mobile commerce products, as well as white label mobile wallet and payment solutions. It also provides prepaid card programs for businesses and consumers; and traditional financial services for merchants separate from the Platform or using select features from it. The company was formerly known as Infantly Available, Inc. and changed its name to IFAN Financial, Inc. in September 2014. IFAN Financial, Inc. was founded in 2010 and is based in San Diego, California.
Full IFAN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.